Currently, there is no corresponding IVD with CDx approval, even though there are commercial IVD tests available determining the hormone receptor status in breast cancer (for example the OncotypeDX assay®, Genomic Health Inc., Redwood City, CA, USA) [30]. This evidence concerns the gene NR4A1 and breast carcinoma.